[go: up one dir, main page]

ME02106B - Miševi sa adam6 - Google Patents

Miševi sa adam6

Info

Publication number
ME02106B
ME02106B MEP-2015-35A MEP201535A ME02106B ME 02106 B ME02106 B ME 02106B ME P201535 A MEP201535 A ME P201535A ME 02106 B ME02106 B ME 02106B
Authority
ME
Montenegro
Prior art keywords
mouse
heavy chain
modification
endogenous
antibody
Prior art date
Application number
MEP-2015-35A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02106(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME02106B publication Critical patent/ME02106B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Description

SEQUENCE LISTING
 
[0372]
 
<110> Lynn Macdonald
 
Sean Stevens
Andrew J. Murphy
 
<120> ADAM6 Miševi
 
<130> 1360A-WO
 
<140> To be assigned
<141>
<150> 61/595,200
<151> 2012-02-06
<150> 61/497,650
<151> 2011-06-16
<150> 61/446,895
<151> 2011-02-25
<160> 58
<170> FastSEQ for Windows Version 4.0
 
 
 
<210> 1
<211> 754
<212> PRT
<213> Mus musculus
 
 
<400> 1
 
 
 
 
 
 
<210> 2
<211> 756
<212> PRT
<213> Mus musculus
 
 
<400> 2
 
 
 
 
 
<210> 3
<211> 13894
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 3
 
 
 
 
 
 
 
 
 
 
 
<210> 4
<211> 251
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 4
 
 
 
<210> 5
<211> 245
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 5
 
 
 
<210> 6
<211> 21
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 6
 
 
<210> 7
<211> 21
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 7
 
 
 
<210> 8
<211> 17
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 8
 
 
 
<210> 9
<211> 24
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 9
 
 
 
<210> 10
<211> 24
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 10
 
 
 
<210> 11
<211> 17
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 11
 
 
 
<210> 12
<211> 28
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 12
 
 
 
<210> 13
<211> 21
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 13
 
 
 
<210> 14
<211> 19
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 14
 
 
 
<210> 15
<211> 22
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 15
 
 
 
<210> 16
<211> 18
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 16
 
 
 
<210> 17
<211> 16
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 17
 
 
 
<210> 18
<211> 19
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 18
 
 
 
<210> 19
<211> 23
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 19
 
 
<210> 20
<211> 18
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 20
 
 
 
<210> 21
<211> 33
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 21
 
 
 
<210> 22
<211> 48
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 22
 
 
 
<210> 23
<211> 42
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 23
 
 
 
<210> 24
<211> 33
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 24
 
 
 
<210> 25
<211> 36
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 25
 
 
 
<210> 26
<211> 45
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 26
 
 
 
<210> 27
<211> 33
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 27
 
 
 
<210> 28
<211> 39
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 28
 
 
 
<210> 29
<211> 33
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 29
 
 
 
<210> 30
<211> 39
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 30
 
 
 
<210> 31
<211> 36
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 31
 
 
<210> 32
<211> 39
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 32
 
 
 
<210> 33
<211> 60
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 33
 
 
 
<210> 34
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 34
 
 
 
<210> 35
<211> 33
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 35
 
 
 
<210> 36
<211> 42
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 36
 
 
 
<210> 37
<211> 24
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 37
 
 
 
<210> 38
<211> 30
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 38
 
 
 
<210> 39
<211> 18
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 39
 
 
 
<210> 40
<211> 30
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 40
 
 
 
<210> 41
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 41
 
 
 
<210> 42
<211> 26
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 42
 
 
 
<210> 43
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 43
 
 
 
<210> 44
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 44
 
 
 
<210> 45
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 45
 
 
 
<210> 46
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 46
 
 
 
<210> 47
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 47
 
 
 
<210> 48
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 48
 
 
 
<210> 49
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 49
 
 
 
<210> 50
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 50
 
 
 
<210> 51
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 51
 
 
 
<210> 52
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 52
 
 
 
<210> 53
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 53
 
 
 
<210> 54
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 54
 
 
 
<210> 55
<211> 24
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 55
 
 
 
<210> 56
<211> 30
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 56
 
 
 
<210> 57
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 57
 
 
 
<210> 58
<211> 27
<212> DNA
<213> Umjetni Slijed
 
 
<220>
<223> sintetički
 
 
<400> 58
 
 
26
 

Claims (14)

1. Miš koji ima genom koji sadrži modifikaciju lokusa teškog lanca imunoglobulina, naznačen time, da modifikacija uklanja endogenu funkciju ADAM6, koja je povezana sa smanjenjem plodnosti kod mužjaka miševa, miš nadalje sadrži sljedove nukleinskih kiselina koji kodiraju mišji protein ADAM6a, ili njegov ortologni ili homologni ili funkcionalni fragment koji je funkcionalan kod mužjaka miša, i mišji ADAM6b protein ili njegov ortologni ili homologni ili funkcionalni fragment koji je funkcionalan kod mužjaka miša.
2. Miš prema zahtjevu 1, naznačen time, da su sljedovi nukleinskih kiselina na endogenom imunoglobulinskom lokusu i pri čemu su sljedovi nukleinskih kiselina integrirani u genom miša, na položaju različitom od položaja endogenog imunoglobulinskog lokusa.
3. Miš prema bilo kojem od zahtjeva 1 do 2, naznačen time, da modifikacija lokusa teškog lanca imunoglobulina podrazumijeva umetanje jednog ili više ljudskih imunoglobulinskih sljedova ili gdje se modifikacija lokusa teškog lanca imunoglobulina sastoji od zamjene jednog ili više sljeda u lokusu teškog lanca imunoglobulina miša s jednim ili više ljudskih imunoglobulinskih sljedova, pri čemu je poželjno da modifikacija lokusa teškog lanca imunoglobulina sadrži zamjenu varijabilnog genskog sljeda endogenog teškog lanca s humanim varijabilnim genskim sljedom endogenog teškog lanca, i još poželjnije da modifikacija lokusa teškog lanca imunoglobulina sadrži zamjenu jednog ili više endogenih genskih segmenata teških lanaca V (VH) s jednim ili više humanih genskih segmenata teških lanaca V (VH).
4. Postupak za modificiranje lokusa mišjeg teškog lanca imunoglobulina, naznačen time, da sadrži: (a) stvaranje prve modifikacije lokusa mišjeg teškog lanca imunoglobulina, što rezultira uklanjanjem endogene mišje ADAM6 aktivnosti u muških miševa; i, (b) izvođenje druge modifikacije miša kojom se dodaju sljedove nukleinskih kiselina koji omogućavaju mišu ADAM6 aktivnost koja je funkcionalna kod muškog miša, pri čemu je poželjno da se sljedovi nukleinskih kiselina u koraku (b) dodaju na ektopičnom položaju, a navedeni sljed nukleinske kiseline kodira mišji ADAM6a protein ili njegov ortologni ili homologni ili funkcionalni fragment, i mišji ADAM6b protein ili njegov ortologni ili homologni ili funkcionalni fragment.
5. Postupak prema zahtjevu 4, naznačen time, da prva modifikacija sadrži umetanje jedne ili više ljudskih imunoglobulinskih sekvenci ili da prvamodifikacija sadrži zamjenu jedne ili više sekvenci u mišjem lokusu teškog lanca imunoglobulina s jednim ili više ljudskih imunoglobulinskih sekvenci, pri čemu je poželjno da prva modifikacija sadrži zamjenu varijabilnog genskog sljeda endogenog teškog lanca s humanim varijabilnim genskim sljedom teškog lanca, i još poželjnije je da prva modifikacija sadrži zamjenu jednog ili više endogenih VH genskih segmenata s jednim ili više humanih genskih segmenata VH.
6. Postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 5, naznačen time, da se prva i druga modifikacija odvijaju simultano.
7. Izolirana stanica ili tkivo izolirano iz miša, naznačeno time, da je u skladu sa bilo kojim od zahtjeva 1 do 3.
8. Upotreba miša u skladu s patentnim zahtjevom 3, naznačena time, da je namijenjena za generiranje(i) himernog antitijela, a navedeno himerno antitijelo sadrži humane varijabilne regije i mišje konstantne regije,(ii) potpuno humano antitijelo,(iii) potpuno humani Fab fragment, i / ili(iv) potpuno humani F(ab)2 fragment.
9. Postupak za proizvodnju himernog antitijela specifičnog za antigena, naznačen time, da obuhvaća korake:a) imuniziranje miša u skladu s patentnim zahtjevom 3 s antigenom;b) izoliranje najmanje jedne stanice s miša koji proizvodi himerno antitijelo specifično za antigen, a navedeno himerno antitijelo humane varijabilne regije i mišje konstantne regije; i c) kultiviranje barem jedne stanice za proizvodnju himernih antitijela iz koraka b) i dobivanje navedenog himernog antitijela, pri čemu je poželjno da se uzgoj u koraku c) izvodi na najmanje jednoj stanici hibridoma generiranoj iz barem jedne stanice dobivene u koraku b).
10. Postupak za generiranje potpuno ljudskog antitijela specifičnog za antigen, naznačen time, da sadrži sljedeće korake:a) imuniziranje miša s antigenom u skladu s patentnim zahtjevom 3;b) izoliranje najmanje jedne stanice od miša za proizvodnju himernog antitijela specifičnog za antigen, navedeno himerno antitijelo sadrži varijabilne regije čovjeka i konstantne regije miša;c) generiranje barem jedne stanice za proizvodnju potpuno ljudskog antitijela izvedenog iz himernog antitijela iz koraka b) i specifičnog za antigen; id) uzgoj barem jedne stanice za proizvodnju potpuno ljudskog antitijela iz koraka c), i dobivanje navedenog potpuno ljudskog antitijela.
11. Postupak prema bilo kojem od zahtjeva 9 i 10, naznačen time, da je najmanje jedna stanica iz koraka b) splenocit ili B stanica.
12. Postupak prema bilo kojem od zahtjeva 9 do 11, naznačen time, da je antitijelo monoklonsko antitijelo.
13. Postupak prema bilo kojem od zahtjeva 9 do12, naznačen time, da se imunizacija s antigenom iz koraka a) provodi s pomoću proteina, DNA, kombinacije DNA i proteina, ili stanice koje eksprimiraju antigen.
14. Sekvenca nukleinske kiseline koja kodira mišji protein ADAM6a ili njegov ortologni ili homologni ili funkcionalni fragment koji je funkcionalan kod mužjaka miša, i mišji protein ADAM6b ili njegov ortolog ili homolog ili funkcionalni fragment koji je funkcionalan u mužjaka miša, naznačen time, da je namijenjen za uporabu u obnovi ili povećanju plodnosti u mužjaka miša koji ima genom koji sadrži modifikaciju lokusa teškog lanca imunoglobulina, pri čemu modifikacija smanjuje ili otklanja djelovanje endogene ADAM6 funkcije, koja je povezana sa smanjenjem plodnosti kod mužjaka miševa, i pri čemu će navedena sekvenca nukleinske kiseline biti integrirana u genom miša, na endogeni imunoglobulinski lokus ili na položajima različitim od endogenog imunoglobulinskog lokusa.
MEP-2015-35A 2011-02-25 2012-02-24 Miševi sa adam6 ME02106B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP12716101.6A EP2550363B1 (en) 2011-02-25 2012-02-24 Adam6 mice
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (1)

Publication Number Publication Date
ME02106B true ME02106B (me) 2015-10-20

Family

ID=45998616

Family Applications (3)

Application Number Title Priority Date Filing Date
MEP2019272 ME03537B (me) 2011-02-25 2012-02-24
MEP-2015-35A ME02106B (me) 2011-02-25 2012-02-24 Miševi sa adam6
MEP-2020-41A ME03732B (me) 2011-02-25 2012-02-24 Miševi s ADAM6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP2019272 ME03537B (me) 2011-02-25 2012-02-24

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2020-41A ME03732B (me) 2011-02-25 2012-02-24 Miševi s ADAM6

Country Status (31)

Country Link
US (12) US8642835B2 (me)
EP (7) EP2578688B2 (me)
JP (8) JP2014507137A (me)
KR (1) KR101387377B1 (me)
CN (2) CN103429746B (me)
AU (6) AU2012243291B2 (me)
BR (1) BR112013021771B1 (me)
CA (1) CA2820824A1 (me)
CY (5) CY1116301T1 (me)
DE (5) DE14154967T1 (me)
DK (6) DK2813573T1 (me)
ES (6) ES2946169T3 (me)
FI (3) FI2738258T4 (me)
HR (5) HRP20230526T1 (me)
HU (5) HUE046081T2 (me)
IL (4) IL226727A (me)
IN (1) IN2013CN07629A (me)
LT (4) LT2578688T (me)
ME (3) ME03537B (me)
MX (3) MX375115B (me)
MY (1) MY172713A (me)
NZ (2) NZ776770A (me)
PL (5) PL2550363T3 (me)
PT (5) PT2550363E (me)
RS (5) RS59929B1 (me)
RU (2) RU2722373C2 (me)
SG (4) SG192933A1 (me)
SI (5) SI2550363T1 (me)
SM (5) SMT201900581T1 (me)
WO (1) WO2012141798A1 (me)
ZA (1) ZA201305998B (me)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK1523496T3 (da) 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP2311874B1 (en) 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2798950B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
JP5955781B2 (ja) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CN103154255B (zh) * 2010-08-02 2016-04-06 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
CA2841376C (en) 2011-07-05 2023-02-28 Duke University N-terminal deleted gp120 immunogens
SI2739740T1 (sl) * 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
HUE034321T2 (en) 2011-10-17 2018-02-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HRP20190897T1 (hr) * 2011-12-20 2019-09-20 Regeneron Pharmaceuticals, Inc. Laki lanac humaniziranih miševa
ME03611B (me) * 2012-02-01 2020-07-20 Regeneron Pharma Humanizovani miševi koji eksprimiraju teške lance koji sadrže vl domene
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HRP20191409T1 (hr) 2012-04-20 2019-11-15 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
KR102484480B1 (ko) * 2012-06-12 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
CA2899740A1 (en) 2013-02-06 2014-08-14 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
HRP20181151T1 (hr) * 2013-02-20 2018-09-21 Regeneron Pharmaceuticals, Inc. Neljudske životinje s modificiranim sekvencama imunoglobulinskog teškog lanca
PL2967012T3 (pl) * 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3051942B1 (en) 2013-10-01 2020-09-02 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
WO2017123804A1 (en) 2016-01-13 2017-07-20 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
SG11201806427WA (en) 2016-02-16 2018-08-30 Regeneron Pharma Non-human animals having a mutant kynureninase gene
ES2977547T3 (es) * 2016-05-20 2024-08-26 Regeneron Pharma Métodos para romper la tolerancia inmunológica utilizando múltiples ARN guía
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
EP4567119A3 (en) 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
CA3084049A1 (en) 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CA3093060A1 (en) 2018-03-21 2019-09-26 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
HRP20250232T1 (hr) 2018-03-24 2025-04-11 Regeneron Pharmaceuticals, Inc. Genetski modificirani miševi ili štakori za dobijanje terapeutskih antitijela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
CN121100878A (zh) 2018-03-26 2025-12-12 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP7670627B2 (ja) 2019-02-18 2025-04-30 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
AU2020289554A1 (en) 2019-06-05 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3785536B2 (en) * 2019-08-28 2025-09-17 Trianni, Inc. Adam6 knockin mice
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
CN116635413A (zh) 2020-12-23 2023-08-22 再生元制药公司 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
KR102871709B1 (ko) 2021-04-20 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 아르테민에 대한 인간 항체 및 이의 사용 방법
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
IL322397A (en) 2023-02-13 2025-09-01 Regeneron Pharma Treating muscle-related disorders with anti-human CACNG1 antibodies
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
AU2023454911A1 (en) 2023-07-10 2026-01-22 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
KR20250151517A (ko) * 2023-09-15 2025-10-21 사이어젠 바이오싸이언스이즈 (쑤저우) 인코퍼레이티드 항체 제조를 위한 유전자 변형 마우스 및 이의 제조 방법
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
AU2024329875A1 (en) * 2024-01-02 2025-07-17 Gempharmatech Co., Ltd Animal model generating humanized antibody and construction method thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0671951A4 (en) * 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
AU5043200A (en) * 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
DK1523496T3 (da) 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
PL1739691T3 (pl) 2005-06-30 2009-06-30 Borealis Tech Oy Zewnętrzne osłony dla kabli elektroenergetycznych lub telekomunikacyjnych
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AU2007254831B2 (en) 2006-06-02 2012-03-22 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
BRPI0922479A2 (pt) * 2008-12-18 2017-07-25 Univ Erasmus Med Ct Rotterdam Animais transgênicos não humanos que expressam os anticorpos humanizados e uso deles
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP2798950B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
CN110079550A (zh) 2009-12-10 2019-08-02 瑞泽恩制药公司 生产重链抗体的小鼠
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JP5955781B2 (ja) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
SI2739740T1 (sl) 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
HUE034321T2 (en) 2011-10-17 2018-02-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HRP20190897T1 (hr) 2011-12-20 2019-09-20 Regeneron Pharmaceuticals, Inc. Laki lanac humaniziranih miševa
KR102484480B1 (ko) 2012-06-12 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물

Also Published As

Publication number Publication date
DK2738258T1 (da) 2014-11-24
SG10201913160QA (en) 2020-03-30
JP2016135143A (ja) 2016-07-28
JP2018143250A (ja) 2018-09-20
RU2582261C2 (ru) 2016-04-20
EP2813573A1 (en) 2014-12-17
AU2022206806A1 (en) 2022-08-18
DK4067496T3 (da) 2023-06-26
EP2738259B1 (en) 2019-11-27
DK2550363T3 (en) 2015-03-23
IL268671A (en) 2019-10-31
HRP20230526T1 (hr) 2023-09-01
IL273986A (en) 2020-05-31
US20180362663A1 (en) 2018-12-20
EP4067496B1 (en) 2023-03-29
PL2738259T3 (pl) 2020-08-24
MX2020009714A (es) 2020-10-07
DE14176593T1 (de) 2015-03-05
SMT201500061B (it) 2015-05-05
SI2738258T1 (sl) 2020-01-31
US20140213773A1 (en) 2014-07-31
RS59661B2 (sr) 2023-06-30
ES2770424T3 (es) 2020-07-01
ES2748832T3 (es) 2020-03-18
LT2738259T (lt) 2020-03-10
JP2022071051A (ja) 2022-05-13
HUE062552T2 (hu) 2023-11-28
RU2722373C2 (ru) 2020-05-29
EP2578688A1 (en) 2013-04-10
US20130254911A1 (en) 2013-09-26
PT2738258T (pt) 2019-12-10
KR101387377B1 (ko) 2014-04-21
EP2738258B1 (en) 2019-09-25
EP2738259A2 (en) 2014-06-04
PT2738259T (pt) 2020-02-18
US20210105985A1 (en) 2021-04-15
SG10201913155QA (en) 2020-02-27
HRP20191895T1 (hr) 2020-01-10
SMT202000112T1 (it) 2020-05-08
ES2946169T3 (es) 2023-07-13
US20180346598A1 (en) 2018-12-06
ES2758974T5 (es) 2023-06-08
LT4067496T (lt) 2023-06-12
IL261243A (en) 2018-10-31
HRP20191895T4 (hr) 2023-05-12
US9944716B2 (en) 2018-04-17
US20150201589A1 (en) 2015-07-23
AU2025283466A1 (en) 2026-01-22
HK1174490A1 (en) 2013-06-14
PT2550363E (pt) 2015-03-16
DK2813573T1 (da) 2015-01-12
RS64280B1 (sr) 2023-07-31
FI4067496T3 (fi) 2023-05-24
PL2578688T5 (pl) 2023-05-29
EP2550363B1 (en) 2014-12-10
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
US12207628B2 (en) 2025-01-28
EP2550363A1 (en) 2013-01-30
DK2578688T3 (da) 2019-10-28
EP2738258A3 (en) 2014-09-24
WO2012141798A1 (en) 2012-10-18
RS59661B1 (sr) 2020-01-31
LT2578688T (lt) 2019-11-11
US20180346599A1 (en) 2018-12-06
DK4067496T5 (da) 2024-07-22
CN103429746A (zh) 2013-12-04
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
US10072095B2 (en) 2018-09-11
US20120322108A1 (en) 2012-12-20
US9932408B2 (en) 2018-04-03
SI2738259T1 (sl) 2020-06-30
EP2578688B2 (en) 2023-02-08
DK2738258T3 (da) 2019-12-16
JP2014110814A (ja) 2014-06-19
SI2738258T2 (sl) 2023-05-31
MY172713A (en) 2019-12-11
US20150210776A1 (en) 2015-07-30
NZ718688A (en) 2017-07-28
BR112013021771A2 (pt) 2017-07-04
US8642835B2 (en) 2014-02-04
EP2738259A3 (en) 2014-07-30
SI2578688T2 (sl) 2023-05-31
RS59413B2 (sr) 2023-06-30
SG10201405135RA (en) 2014-10-30
DK2578688T4 (da) 2023-05-08
KR20130116375A (ko) 2013-10-23
HUE046746T2 (hu) 2020-03-30
MX2013009649A (es) 2013-09-26
EP2578688B1 (en) 2019-07-24
DE12192727T1 (de) 2013-07-11
SMT201900581T1 (it) 2019-11-13
PL2578688T3 (pl) 2020-05-18
FI2578688T4 (fi) 2023-05-05
IL268671B (en) 2020-05-31
EP3744850A1 (en) 2020-12-02
IL226727A (en) 2016-08-31
MX343009B (es) 2016-10-21
DE14154967T1 (de) 2014-08-28
SI4067496T1 (sl) 2023-07-31
PL4067496T3 (pl) 2023-07-31
DK2738258T4 (da) 2023-05-08
NZ612643A (en) 2015-06-26
BR112013021771B1 (pt) 2022-11-16
CN105861548A (zh) 2016-08-17
US10577430B2 (en) 2020-03-03
RU2016109443A3 (me) 2019-07-24
US10905109B2 (en) 2021-02-02
CY1126091T1 (el) 2023-11-15
EP2738258B2 (en) 2023-02-01
NZ703609A (en) 2016-04-29
ES2805364T3 (es) 2021-02-11
RU2016109443A (ru) 2018-11-26
NZ797720A (en) 2024-09-27
JP2015107131A (ja) 2015-06-11
IL273986B (en) 2021-04-29
RU2013125717A (ru) 2014-12-10
CY1122820T1 (el) 2021-05-05
AU2015238806A1 (en) 2015-10-29
US8697940B2 (en) 2014-04-15
ME03537B (me) 2020-04-20
ME03732B (me) 2021-01-20
DE14154918T1 (de) 2014-08-21
ZA201305998B (en) 2016-07-27
EP2738258A2 (en) 2014-06-04
DK2738259T1 (da) 2014-11-24
JP2014507137A (ja) 2014-03-27
ES2532487T3 (es) 2015-03-27
FI2738258T4 (fi) 2023-05-05
IL261243B (en) 2019-08-29
HK1201292A1 (en) 2015-08-28
US20210105984A1 (en) 2021-04-15
SMT201900744T1 (it) 2020-01-14
HUE024534T2 (hu) 2016-01-28
IN2013CN07629A (me) 2015-08-07
US10905108B2 (en) 2021-02-02
JP2025032218A (ja) 2025-03-11
US20180345760A1 (en) 2018-12-06
HRP20200294T1 (hr) 2020-05-29
JP5866127B2 (ja) 2016-02-17
HRP20192311T4 (hr) 2023-05-12
PL2550363T3 (pl) 2015-05-29
SG192933A1 (en) 2013-09-30
JP2019187446A (ja) 2019-10-31
CY1122459T1 (el) 2021-01-27
AU2022206806B2 (en) 2025-10-02
CY1122205T1 (el) 2020-11-25
RS59929B1 (sr) 2020-03-31
PT4067496T (pt) 2023-06-07
HRP20192311T1 (hr) 2020-03-20
MX375115B (es) 2025-03-06
NZ776770A (en) 2023-03-31
DE12716101T1 (de) 2013-05-08
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
RS53880B1 (sr) 2015-08-31
EP4067496A1 (en) 2022-10-05
DK2578688T1 (da) 2014-11-24
CY1116301T1 (el) 2017-02-08
AU2012243291B2 (en) 2015-07-09
CN105861548B (zh) 2020-01-10
NZ731926A (en) 2021-07-30
SMT202300173T1 (it) 2023-07-20
US10694725B2 (en) 2020-06-30
AU2020201279A1 (en) 2020-03-12
AU2012243291A1 (en) 2013-05-09
AU2017251802A1 (en) 2017-11-16
US20240306617A1 (en) 2024-09-19
DK2738259T3 (da) 2020-02-17
PL2738258T3 (pl) 2020-08-24
CN103429746B (zh) 2016-05-11
RS59413B1 (sr) 2019-11-29
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
SI2578688T1 (sl) 2019-11-29
LT2738258T (lt) 2020-01-10
HRP20150262T1 (hr) 2015-04-10
CA2820824A1 (en) 2012-10-18
ES2748832T5 (es) 2023-06-08

Similar Documents

Publication Publication Date Title
ME02106B (me) Miševi sa adam6
HRP20171357T1 (hr) Ograničeni teški lanac imunoglobulina u miševa
HRP20210916T1 (hr) Miševi s ljudskim univerzalnim lakim lancem
HRP20200093T1 (hr) Humanizirane neljudske životinje s ograničenim lokusima imunoglobulinskog teškog lanca
JP6185978B2 (ja) ヒスチジン操作された軽鎖抗体およびこれを作製するための遺伝子改変された非ヒト動物
JP6479024B2 (ja) 抗体親和性の最適化のための高スループットマウスモデル
HRP20201403T1 (hr) Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca
JP2015519076A5 (me)
JP2011182801A5 (me)
HRP20200613T1 (hr) Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt
JP2012532598A5 (me)
JP2014110814A5 (me)
JP2020501516A5 (me)
JP2010536396A5 (me)
TR201909967T4 (tr) Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar.
TR201901668T4 (tr) Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
AU2021283564B2 (en) Genetically modified non-human animals with common light chain immunoglobulin locus
JP2013539369A5 (me)
CA2979702A1 (en) Non-human animals that select for light chain variable regions that bind antigen
WO2012122512A1 (en) Recombinant production of mixtures of single chain antibodies
KR20170092678A (ko) 최적화된 치료 분자를 제조하는 방법
JP7779655B2 (ja) ヒト型抗体を産生するトランスジェニックニワトリ
CN103739707B (zh) 抗禽流感h5n1血凝素抗原的人源化抗体及其制备方法和用途
WO2022248445A1 (en) Animal models and therapeutic molecules
WO2023247779A1 (en) Animal models and therapeutic molecules